These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15306945)

  • 41. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
    Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
    Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mesonephric remnant hyperplasia involving prostate and periprostatic tissue: findings at radical prostatectomy.
    Chen YB; Fine SW; Epstein JI
    Am J Surg Pathol; 2011 Jul; 35(7):1054-61. PubMed ID: 21606823
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ductal adenocarcinoma of the prostate with endometrioid features in a 69-year-old man.
    Cheng CJ; Chen KC; Chen WY; Su SJ
    J Formos Med Assoc; 2001 Oct; 100(10):707-11. PubMed ID: 11760379
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
    Wang W; Epstein JI
    Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma.
    Mhawech P; Uchida T; Pelte MF
    Hum Pathol; 2002 Nov; 33(11):1136-40. PubMed ID: 12454820
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Triple cancer: chronic lymphocytic leukemia with bladder and prostate carcinoma.
    Gajendra S; Sharma R; Sahoo MK
    Malays J Pathol; 2015 Aug; 37(2):159-63. PubMed ID: 26277675
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Morphological features correlation with serum tumour markers in prostatic carcinoma.
    Afzal S; Ahmad M; Mushtaq S; Mubarik A; Qureshi AH; Khan SA
    J Coll Physicians Surg Pak; 2003 Sep; 13(9):511-4. PubMed ID: 12971871
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The distribution of PAX-2 immunoreactivity in the prostate gland, seminal vesicle, and ejaculatory duct: comparison with prostatic adenocarcinoma and discussion of prostatic zonal embryogenesis.
    Quick CM; Gokden N; Sangoi AR; Brooks JD; McKenney JK
    Hum Pathol; 2010 Aug; 41(8):1145-9. PubMed ID: 20413145
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes of phenotypic expression of prostatic antigen in secondary transitional cell carcinoma of the prostate: evidence for induction phenomenon as a mechanism for acquisition of prostatic antigens in prostatic transitional cell carcinoma.
    Mai KT; Yazdi HM; Farmer J
    Prostate; 2001 May; 47(3):172-82. PubMed ID: 11351346
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pure prostatic papillary adenocarcinoma with ductal features.
    Yamashita S; Inaba Y; Soma F; Katayama Y
    Hinyokika Kiyo; 2005 Mar; 51(3):207-9; discussion 210. PubMed ID: 15852679
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
    Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
    Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prostate Ductal Adenocarcinoma.
    Amin A
    Appl Immunohistochem Mol Morphol; 2018 Aug; 26(7):514-521. PubMed ID: 28362706
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.
    Morais CL; Herawi M; Toubaji A; Albadine R; Hicks J; Netto GJ; De Marzo AM; Epstein JI; Lotan TL
    Prostate; 2015 Oct; 75(14):1610-9. PubMed ID: 26178158
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fine needle aspiration cytology of a metastatic duct carcinoma of the prostate: a case report.
    Alrahwan D; Staerkel G; Gong Y
    Acta Cytol; 2006; 50(4):469-72. PubMed ID: 16901017
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens.
    Pacelli A; Bostwick DG
    Urology; 1997 Sep; 50(3):355-9. PubMed ID: 9301697
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunohistochemical verification of ductal differentiation in prostate cancer.
    Tarján M; Lenngren A; Hellberg D; Tot T
    APMIS; 2012 Jun; 120(6):510-8. PubMed ID: 22583364
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A case of prostatic duct adenocarcinoma: its clinical significance in comparison with typical acinar adenocarcinoma.
    Takazawa R; Kawakami S; Yamamoto K; Kubo Y; Kageyama Y; Kihara K
    Hinyokika Kiyo; 2008 Mar; 54(3):243-7. PubMed ID: 18411784
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non-prostatic origin: a comparative study.
    Seipel AH; Samaratunga H; Delahunt B; Wiklund P; Clements M; Egevad L
    APMIS; 2016 Apr; 124(4):263-70. PubMed ID: 26778368
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Urothelial carcinoma of the prostate.
    Goebbels R; Amberger L; Wernert N; Dhom G
    Appl Pathol; 1985; 3(4):242-54. PubMed ID: 3842265
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Prognostic significance of cell proliferation, microvascular density and androgen receptor level in prostatic adenocarcinoma].
    Lefterov SI; Gorelov SI; Krivolapov IuA
    Vopr Onkol; 2009; 55(6):740-5. PubMed ID: 20210018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.